Division of Pathology, Department of Pathology, Kobe University Graduate School of Medicine, Kobe, Japan; Division of Gastro-intestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Division of Pathology, Department of Pathology, Kobe University Graduate School of Medicine, Kobe, Japan.
Am J Pathol. 2021 Apr;191(4):686-703. doi: 10.1016/j.ajpath.2021.01.004. Epub 2021 Jan 16.
Tumor-associated macrophages (TAMs) promote tumor progression. The number of infiltrating TAMs is associated with poor prognosis in esophageal squamous cell carcinoma (ESCC) patients; however, the mechanism underlying this phenomenon is unclear. cDNA microarray analysis indicates that the expression of chemokine (C-C motif) ligand 1 (CCL1) is up-regulated in peripheral blood monocyte-derived macrophages stimulated using conditioned media from ESCC cells (TAM-like macrophages). Here, we evaluated the role of CCL1 in ESCC progression. CCL1 was overexpressed in TAM-like macrophages, and CCR8, a CCL1 receptor, was expressed on ESCC cell surface. TAM-like macrophages significantly enhanced the motility of ESCC cells, and neutralizing antibodies against CCL1 or CCR8 suppressed this increased motility. Recombinant human CCL1 promoted ESCC cell motility via the Akt/proline-rich Akt substrate of 40 kDa/mammalian target of rapamycin pathway. Phosphatidylinositol 3-kinase or Akt inhibitors, CCR8 silencing, and neutralizing antibody against CCR8 could significantly suppress these effects. The overexpression of CCL1 in stromal cells or CCR8 in ESCC cells was significantly associated with poor overall survival (P = 0.002 or P = 0.009, respectively) and disease-free survival (P = 0.009 or P = 0.047, respectively) in patients with ESCC. These results indicate that the interaction between stromal CCL1 and CCR8 on cancer cells promotes ESCC progression via the Akt/proline-rich Akt substrate of 40 kDa/mammalian target of rapamycin pathway, thereby providing novel therapeutic targets.
肿瘤相关巨噬细胞(TAMs)促进肿瘤进展。浸润 TAMs 的数量与食管鳞状细胞癌(ESCC)患者的预后不良相关;然而,其潜在机制尚不清楚。cDNA 微阵列分析表明,在 ESCC 细胞条件培养基刺激下,外周血单核细胞来源的巨噬细胞(TAM 样巨噬细胞)中趋化因子(C-C 基序)配体 1(CCL1)的表达上调。在此,我们评估了 CCL1 在 ESCC 进展中的作用。TAM 样巨噬细胞中 CCL1 过表达,而 CCL1 受体 CCR8 则表达于 ESCC 细胞表面。TAM 样巨噬细胞显著增强了 ESCC 细胞的迁移能力,而针对 CCL1 或 CCR8 的中和抗体则抑制了这种迁移能力的增强。重组人 CCL1 通过 Akt/富含脯氨酸的 Akt 底物 40 kDa/雷帕霉素靶蛋白途径促进 ESCC 细胞的迁移。PI3K 或 Akt 抑制剂、CCR8 沉默和 CCR8 中和抗体均可显著抑制这些作用。在 ESCC 患者中,基质细胞中 CCL1 的过表达或 ESCC 细胞中 CCR8 的过表达与总生存期(P=0.002 或 P=0.009)和无病生存期(P=0.009 或 P=0.047)显著相关。这些结果表明,基质细胞 CCL1 与癌细胞上的 CCR8 之间的相互作用通过 Akt/富含脯氨酸的 Akt 底物 40 kDa/雷帕霉素靶蛋白途径促进 ESCC 进展,从而为新的治疗靶点提供了依据。